Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 2000

Filing Date
Filed March 13, 2001
Period End
December 31, 2000
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K filed March 13, 2001. Cited figures are marked; the original filing is the authoritative source.

Schering-Plough Corporation, now Merck & Co., Inc., reported 2000 net sales of $9.8 billiona, up 8 percent from $9.1 billion in 1999, with net income rising 15 percent to $2.4 billion ($2,423 million) and diluted earnings per share of $1.64.

Growth was led by allergy and respiratory products, where CLARITIN sales reached $3.0 billionb, and by anti-infective and anticancer products, where INTRON A/REBETRON Combination Therapy totaled $1.4 billion, up 21 percent. Income before income taxes was $3.2 billion, the effective tax rate fell to 24.0 percent, and cash provided by operating activities was $2.5 billion. The filing is dominated by risk disclosures.

The FDA has cited current Good Manufacturing Practice deficiencies at the company's New Jersey and Puerto Rico facilities, and the company said that manufacturing process and control issues reduced U.S. sales of certain products, so first-quarter and full-year 2001 sales and earnings will be lower than expected. The FDA has said these deficiencies must be resolved before it approves the pending NDA for CLARINEX (desloratadine) Tablets. Following the February 2001 announcement, shareholder securities class actions were filed, and Standard & Poor's and Moody's revised their long-term debt outlooks to negative.

The company also faces CLARITIN generic challenges, with loratadine's U.S. compound patent expiring in 2002, and numerous antitrust, investigation and product liability matters. The balance sheet remained solid, with cash of $2.4 billionc and a debt-to-total-capital ratio of 15 percent, up from 12 percent in 1999. Shareholders' equity rose to $6.1 billion.

Share repurchases totaled $855 milliond in 2000, and dividends paid were $802 million, or $0.545 per share. Cash and cash equivalents were $2,397 million at year-end.

Key Highlights

  1. Net sales rose 8 percent to $9.8 billion in 2000, with U.S. sales up 9 percent and international sales up 6 percent.
  2. Net income increased 15 percent to $2.4 billion, and diluted EPS rose 15 percent to $1.64.
  3. CLARITIN brand sales totaled $3.0 billion in 2000, up 13 percent, though the filing notes market share declines.
  4. INTRON A/REBETRON Combination Therapy sales reached $1.4 billion, up 21 percent.
  5. The FDA cited GMP deficiencies at New Jersey and Puerto Rico facilities; the company expects lower first-quarter and full-year 2001 sales and earnings, and CLARINEX approval depends on resolving these deficiencies.
  6. Shareholder class actions were filed after the February 15, 2001 announcement, covering purchasers from July 25, 2000 to February 15, 2001.
  7. Research and development spending rose 12 percent to $1.33 billion, or 13.6 percent of net sales.

Frequently Asked Questions

  1. Why did the company warn that 2001 sales and earnings would be lower than expected?

    The company reported that manufacturing process and control issues, cited by the FDA in inspections of its New Jersey and Puerto Rico facilities, reduced sales of certain products in the U.S. The extent of the impact will depend on the timing and nature of a resolution of the manufacturing issues.

  2. What is the status of the CLARINEX (desloratadine) approval?

    The NDA for CLARINEX Tablets is pending. The FDA has advised that GMP deficiencies cited in facility inspection reports must be resolved before it grants approval.

  3. How is the company's CLARITIN franchise exposed to competition?

    The loratadine compound patent for CLARITIN in the United States expires in 2002, and the desloratadine compound patent expires in 2004. Several generic companies have filed ANDAs challenging these patents, and the company has filed or will file suits seeking rulings of willful infringement. The filing also notes that the FDA will hold a joint advisory committee meeting on May 11, 2001 or later to consider a citizens' petition seeking the OTC switch of loratadine and two other antihistamines.

  4. What are the largest legal exposures disclosed?

    The company faces 235 lawsuits involving approximately 400 plaintiffs over synthetic estrogen use, with claims totaling more than $1.5 billion, and management views material liability beyond accrued amounts as remote. Other matters include about 100 antitrust actions, an FTC investigation of drug price conspiracy allegations, a Puerto Rico class action claiming $600 million in damages, a Texas suit seeking $54 million from its generic subsidiary Warrick, and an injunction barring sales of its PRIME PAC PRRS vaccine.

  5. How strong is the company's financial position?

    At December 31, 2000, cash and cash equivalents were $2.4 billion, and shareholders' equity was $6.1 billion. The debt-to-total-capital ratio was 15 percent, up from 12 percent in 1999. Operating cash flow was $2.5 billion, and the company had $1.3 billion in unused lines of credit. Standard & Poor's and Moody's affirmed the ratings but revised their outlook on long-term debt to negative.